Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 1Dermatologic 1

Conditions

Prostatic Neoplasms 15Carcinoma, Non-Small-Cell Lung 9Uterine Cervical Neoplasms 7Colonic Neoplasms 6Breast Neoplasms 5Uterine Cervical Dysplasia 4Urinary Bladder Neoplasms 4Papillomavirus Infections 3Neuroblastoma 3Melanoma 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Esophageal Neoplasms 3Brain Neoplasms 3Anus Neoplasms 3Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Squamous Intraepithelial Lesions 2Rectal Neoplasms 2Precancerous Conditions 2Oropharyngeal Neoplasms 2Neoplasms 2Mouth Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Liver Neoplasms 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2HIV Infections 2

Interventions

Cisplatin 160Fluorouracil 134Paclitaxel 125Radiotherapy 117Oxaliplatin 87Carboplatin 71Docetaxel 70Irinotecan 59pembrolizumab 57Capecitabine 57Leucovorin 56Radiation 47Surgical Procedures, Operative 33Drug Therapy 33Esophagectomy 31Cetuximab 25Neoadjuvant Therapy 24Nivolumab 23Bevacizumab 21Trastuzumab 20camrelizumab 19S 1 (combination) 19Chemoradiotherapy 17Albumin-Bound Paclitaxel 16Magnetic Resonance Spectroscopy 15Epirubicin 15tislelizumab 14Taxes 13Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Esophageal Neoplasms × Watchful Waiting × Clear all
NCT05953181 2024-09-19

SANO

Erasmus Medical Center

Phase NA Active not recruiting
776 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT04135664 2019-10-22

Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma

Shanghai Chest Hospital

Phase 3 Recruiting
176 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT03220009 2018-10-03

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicGastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡